

**FORM 51-102F3**  
**MATERIAL CHANGE REPORT**

**Item 1.      Name and Address of Company**

Abattis Bioceuticals Corp.  
1000 - 355 Burrard Street  
Vancouver, BC V6C 2G8

**Item 2.      Date of Material Change**

July 7, 2014

**Item 3.      News Release**

A news release dated and disseminated July 7, 2014 at Vancouver, British Columbia, through The Newswire.ca, CSE Markets and SEDAR is attached as Schedule "A".

**Item 4.      Summary of Material Change**

See news release, a copy of which is attached hereto.

**Item 5.      Full Description of Material Change**

See news release, a copy of which is attached hereto.

**Item 6.      Reliance on subsection 7.1(2) or (3) of National Instrument 51-102**

Not applicable.

**Item 7.      Omitted Information**

Not applicable.

**Item 8.      Executive Officer**

Michael Withrow, President & CEO  
Telephone: 604.538.6650

**Item 9.      Date of Report**

July 14, 2014

---

## **ABATTIS INFORMATION AVAILABLE ON S&P CAPITAL IQ**

**Vancouver, BC – July 7, 2014 - Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (OTC PINK: ATTBF) (CSE: ATT),** a specialty biotechnology company focused on cultivating, licensing, and marketing proprietary ingredients, bio-similar compounds, equipment, and consulting services to North American medicinal markets, today announced that its company information would be made available via S&P Capital IQ Corporation Record’s Listing Program. This is one of the final steps in the Company elevating to the OTC QX in the upcoming months.

“We are excited to enhance our visibility within the investment community via the S&P Capital IQ’s program,” said Abattis Bioceuticals Corp. President & CEO Mike Withrow. “Our company is rapidly approaching a key tipping point with several subsidiaries moving forward with licensing through Health Canada. Management is committing to unlocking shareholder value through both operational excellence and increased market awareness through programs like these.”

As part of the program, a full description of Abattis Bioceuticals Corp. will be published in the Daily News Section of Standard & Poors’s Corporation Records, a recognized securities manual for secondary trading in up to 38 States under the Blue Sky Laws. S&P Capital IQ Corporation Records is available in print, CD-ROM, and via the web at [www.netadvantage.standardandpoors.com](http://www.netadvantage.standardandpoors.com) as well as through numerous electronic vendors.

The company information about Abattis Bioceuticals Corp. to be made available through this program includes an in-depth description of the Abattis’ business operations, share price, dividend history, shares outstanding, company financial position, earnings, and full income statement and balance sheet.

### **About Abattis Bioceuticals Corp.**

Abattis is a specialty biotechnology company with capabilities through its wholly owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America. The Company is positioned to capitalize on the fast growing trend toward marijuana legalization in the United States and for medicinal use in Canada and international jurisdictions, by supplying and partnering with companies to employ its mass cultivation systems, extraction equipment/technology, and strategic marketing support to licensed growers. The Company also has an extensive pipeline of high-quality products and intellectual property for the rapidly expanding botanical drug market. We follow strict standard operating protocols, and adhere to the applicable laws of Canada and foreign jurisdictions. For more information, visit the Company's website at: [www.abattis.com](http://www.abattis.com).

### **About S&P Capital IQ**

S&P Capital IQ, a business unit of McGraw Hill Financial (NYSE:MHFI), is a leading provider of multi-asset class and real time data, research and analytics to institutional investors, investment and commercial banks,

investment advisors and wealth managers, corporations and universities around the world. S&P Capital IQ provides a broad suite of capabilities designed to help track performance, generate alpha, and identify new trading and investment ideas, and perform risk analysis and mitigation strategies. Through leading desktop solutions such as the S&P Capital IQ, Global Credit Portal and MarketScope Advisor desktops; enterprise solutions such as S&P Capital IQ Valuations; and research offerings, including Leveraged Commentary & Data, Global Markets Intelligence, and company and funds research, S&P Capital IQ sharpens financial intelligence into the wisdom today's investors need. For more information visit: [www.spcapitaliq.com](http://www.spcapitaliq.com)

In the United States, research reports are prepared by Standard & Poor's Investment Advisory Services LLC, a part of S&P Capital IQ and a registered investment adviser with the U.S. Securities and Exchange Commission. Company information distributed through the Corporation Records Program is based upon information that S&P Capital IQ considers to be reliable, but neither S&P Capital IQ nor its affiliates warrant its completeness or accuracy, and it should not be relied upon as such. This material is not intended as an offer or solicitation for the purchase or sale of any security or other financial instrument.

#### ON BEHALF OF THE BOARD

***"Mike Withrow"***

Michael Withrow, President & CEO

For further information, contact the Company's CEO, Michael Withrow at (778) 896-6536 or at [news@abattis.com](mailto:news@abattis.com).

***NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.***

#### FORWARD LOOKING INFORMATION

This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company's Management's Discussion and Analysis under the Company's profile on [www.sedar.com](http://www.sedar.com). While the Company may elect to, it does not undertake to update this information at any particular time.